Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-155058
Filing Date
2026-04-14
Accepted
2026-04-14 17:00:16
Documents
19
Period of Report
2026-05-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A rgnx-20260414.htm   iXBRL DEF 14A 1320142
2 GRAPHIC img243527914_0.jpg GRAPHIC 19663
3 GRAPHIC img243527914_1.jpg GRAPHIC 32056
4 GRAPHIC img243527914_2.jpg GRAPHIC 26460
5 GRAPHIC img243527914_3.gif GRAPHIC 155786
6 GRAPHIC img243527914_4.gif GRAPHIC 168928
7 GRAPHIC img243527914_5.jpg GRAPHIC 479187
8 GRAPHIC img243527914_6.jpg GRAPHIC 205600
  Complete submission text file 0001193125-26-155058.txt   4603334

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rgnx-20260414.xsd EX-101.SCH 26449
22 EXTRACTED XBRL INSTANCE DOCUMENT rgnx-20260414_htm.xml XML 124955
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37553 | Film No.: 26861499
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)